BioLineRx (NASDAQ:BLRX) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

BioLineRx Ltd. (NASDAQ:BLRX)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.92 and traded as high as $3.11. BioLineRx shares last traded at $3.11, with a volume of 22,621 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

BioLineRx Stock Performance

The stock has a market cap of $13.53 million, a price-to-earnings ratio of -18.29 and a beta of 1.42. The stock’s fifty day moving average is $2.55 and its 200-day moving average is $2.92. The company has a quick ratio of 1.78, a current ratio of 1.95 and a debt-to-equity ratio of 0.19.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Tuesday, March 24th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.16. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.49 million. BioLineRx had a negative net margin of 99.58% and a negative return on equity of 5.61%.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.